Stereotaxis (STXS) Stock Price, News & Analysis

Company Overview

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane, full-power x-ray system, including c-arm, powered table, motorized boom, and monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. It markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with MAGiC catheter for cardiac ablation procedures. Stereotaxis, Inc. was incorporated in 1990 and is based in Saint Louis, Missouri.

Key Stats

• Today's Range: $2.20 to $2.36
• 50-Day Range: N/A
• 52-Week Range: $1.66 to $3.29
• Volume: 874,857 shs
• Average Volume: 311,756 shs
• Market Capitalization: $199.12 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.50
• Consensus Rating: Buy

Stereotaxis Stock Analysis - MarketRank™

Stereotaxis scored higher than 60% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Stereotaxis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Stereotaxis has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Stereotaxis are expected to grow in the coming year, from ($0.26) to ($0.16) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Stereotaxis is -8.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Stereotaxis is -8.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Stereotaxis has a P/B Ratio of 11.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.63% of the float of Stereotaxis has been sold short.

Short Interest Ratio / Days to Cover

Stereotaxis has a short interest ratio ("days to cover") of 8.7.

Change versus previous month

Short interest in Stereotaxis has recently decreased by 17.26%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Stereotaxis does not currently pay a dividend.

Dividend Growth

Stereotaxis does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.63% of the float of Stereotaxis has been sold short.

Short Interest Ratio / Days to Cover

Stereotaxis has a short interest ratio ("days to cover") of 8.7.

Change versus previous month

Short interest in Stereotaxis has recently decreased by 17.26%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: N/A

News Sentiment

Stereotaxis has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Medical companies.

Search Interest

3 people have searched for STXS on MarketBeat in the last 30 days.

MarketBeat Follows

Only 1 people have added Stereotaxis to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Stereotaxis insiders have not sold or bought any company stock.

Percentage Held by Insiders

18.52% of the stock of Stereotaxis is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

45.35% of the stock of Stereotaxis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

STXS Stock Analysis - Frequently Asked Questions

How have STXS shares performed this year?

Stereotaxis' stock was trading at $2.87 at the beginning of the year. Since then, STXS shares have decreased by 18.1% and is now trading at $2.35.
View the best growth stocks for 2024 here.

How were Stereotaxis' earnings last quarter?

Stereotaxis, Inc. (NYSEAMERICAN:STXS) issued its earnings results on Monday, November, 11th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.05) by $0.03. The firm earned $9.20 million during the quarter, compared to analysts' expectations of $6.80 million. Stereotaxis had a negative trailing twelve-month return on equity of 162.54% and a negative net margin of 85.79%.

Who are Stereotaxis' major shareholders?

Top institutional investors of Stereotaxis include Geode Capital Management LLC (1.64%), State Street Corp (0.80%), Charles Schwab Investment Management Inc. (0.20%) and Kovack Advisors Inc. (0.15%).
View institutional ownership trends.

How do I buy shares of Stereotaxis?

Shares of STXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Stereotaxis own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Stereotaxis investors own include Tesla (TSLA), Advanced Micro Devices (AMD), NVIDIA (NVDA), Intel (INTC), Meta Platforms (META), JPMorgan Chase & Co. (JPM) and Netflix (NFLX).

Company Calendar

• Last Earnings: 11/11/2024
• Today: 12/22/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: Electromedical equipment
• Sub-Industry: Medical Equipment
• Current Symbol: NYSEAMERICAN:STXS
• CUSIP: N/A
• CIK: 1289340
• Web: www.stereotaxis.com
• Phone: (314) 678-6100
• Fax: 314-678-6159
• Employees: 130
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $4.50
• High Stock Price Target: $5.00
• Low Stock Price Target: $4.00
• Potential Upside/Downside: +91.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.28)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-20,710,000.00
• Net Margins: -85.79%
• Pretax Margin: -85.79%
• Return on Equity: -162.54%
• Return on Assets: -51.26%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.39
• Quick Ratio: 0.96

Sales & Book Value

• Annual Sales: $26.77 million
• Price / Sales: 7.44
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.20 per share
• Price / Book: 11.75

Miscellaneous

• Outstanding Shares: 84,730,000
• Free Float: 69,038,000
• Market Cap: $199.12 million
• Optionable: Not Optionable
• Beta: 1.57